Drugmaker Ionis's Q2 revenue doubles, beats expectations; hikes guidance

Ionis Pharmaceuticals

30/07/2025 12:11

Overview

Ionis Q2 2025 revenue doubles yr/yr, beating analyst expectations

Adjusted operating income beats expectations, driven by TRYNGOLZA launch

Co raises 2025 financial guidance, citing improved outlook and performance

Outlook

Ionis raises 2025 revenue guidance to $825-850 mln

Company expects TRYNGOLZA sales of $75-80 mln in 2025

Ionis anticipates sustained growth and positive cash flow

Result Drivers

TRYNGOLZA LAUNCH - Strong revenue growth driven by TRYNGOLZA's successful launch, generating $19 mln in Q2 sales

ROYALTY REVENUE - Increased royalty revenue from products like SPINRAZA and WAINUA contributed to revenue growth

COMMERCIAL INVESTMENTS - Operating expenses rose due to investments in commercializing TRYNGOLZA, donidalorsen, and WAINUA

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$452 mln
$295.20 mln (19 Analysts)
Q2 Net Income
$124 mln
Q2 Adjusted Operating Income
Beat
$170 mln
-$44.90 mln (12 Analysts)
Q2 Adjusted Operating Expenses
$282 mln
Q2 Operating Expenses
$312 mln
Q2 Operating Income
$140 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 8 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Ionis Pharmaceuticals Inc is $58.00, about 28.5% above its July 29 closing price of $41.48

Press Release: ID:nBwfCpmBa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)